JUN 22, 2020 3:36 PM PDT

MDMA Has Long-Term Benefits Against PTSD

WRITTEN BY: Annie Lennon

Researchers have shown that MDMA-assisted psychotherapy has therapeutic effects that last over a year in treating post-traumatic stress disorder (PTSD). 

The new paper explores the long-term outcomes for people a year after completing MDMA psychotherapies. Comprising follow-up data from six previous trials, all in all, the researchers gathered data on around 100 patients. 

Participants in each trial underwent two to three therapy sessions with active doses of MDMA (75-125mg) alongside additional regular psychotherapy sessions. Their PTSD symptoms were measured using the Clinician-Administered PTSD Scale for DSM IV at baseline either one or two months following their last MDMA session, and then at least 12 months after that. Each participant also filled in a long-term follow-up survey. 

At the first follow-up, the researchers noted that 56% of the cohort no longer met the clinical criteria for PTSD. However, after the second follow-up, they found that participants tended to continue to improve over the year. This meant that 12 months on from the MDMA-sessions, 67% of the cohort no longer met the criteria for PTSD. 

The researchers also noted that after treatment, patients tended to have fewer suicidal thoughts and general PTSD symptoms. Their data also suggested that MDMA therapy does not lead to MDMA abuse nor any other substance abuse. 

"These long-term follow-up findings show that once people with PTSD learn that they can productively process traumatic memories instead of suppressing them, they can continue to heal themselves even after they have stopped receiving MDMA-assisted psychotherapy," says Rick Doblin, one of the authors of the study. 

Following the success of these Phase II trials, MDMA-assisted therapy is now in Phase III human trials for severe, treatment-resistant PTSD, with US Food and Drug Administration (FDA) approval expected in 2022. 

Meanwhile, due to the effectiveness of the treatment, earlier this year, the FDA approved it for Expanded Access, allowing select patients to access the procedure before it has full-market approval. 


Sources: New Atlas, Springer,

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
JUL 20, 2020
Cancer
Fighting Cancer with Black Pepper
JUL 20, 2020
Fighting Cancer with Black Pepper
In the never-ending search for the next treatment or cure, many researchers turn towards nature. The study of black pepp ...
JUL 21, 2020
Cardiology
Investigating New Anti-Blood Clotting Treatments
JUL 21, 2020
Investigating New Anti-Blood Clotting Treatments
When it comes to your cardiovascular health, it is important to look at more than just your heart. The cardiovascular sy ...
JUL 13, 2020
Drug Discovery & Development
Potential Therapy for The Dengue Virus
JUL 13, 2020
Potential Therapy for The Dengue Virus
Researchers at the University of Texas Medical Branch at Galveston have uncovered a new antiviral mechanism for the new ...
AUG 16, 2020
Neuroscience
Study Says Social Connection Best Way to Prevent Depression
AUG 16, 2020
Study Says Social Connection Best Way to Prevent Depression
Depression is the world's leading source of disability. Now, researchers from Massachusetts General Hospital (MGH) h ...
AUG 16, 2020
Drug Discovery & Development
Could Cat Drugs Treat COVID-19 in Humans?
AUG 16, 2020
Could Cat Drugs Treat COVID-19 in Humans?
While COVID-19 may not affect cats much, felines are known to contract another kind of coronavirus that can sometimes be ...
AUG 17, 2020
Drug Discovery & Development
Therapy Found in The Shell of Cashews
AUG 17, 2020
Therapy Found in The Shell of Cashews
A compound found in the shell of cashews can help in neurodegeneration. "We see this as an exciting finding, sugges ...
Loading Comments...